A 74-year-old man was referred for a Ga-prostate-specific membrane antigen (PSMA) PET/CT scan for newly diagnosed prostate cancer which confirmed the presence of PSMA avid cancer in the right gland with no evidence of PSMA metastasis. Incidentally, there was a markedly PSMA avid (SUVmax 7.0) lobulated periventricular mass in the region of the left basal ganglia which was T2 hyperintense and T1 hypointense with perilesional oedema and vivid Gadolinium enhancement on MRI. The patient underwent stereotactic guided biopsy which confirmed LHD wild-type glioblastoma (WHO grade IV).
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9010689 | PMC |
| http://dx.doi.org/10.1016/j.radcr.2022.03.050 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
A novel tool to predict lymph node metastasis in patients with prostate cancer based on clinical and Ga-PSMA PET/CT parameters.
Can Urol Assoc J
December 2024
Department of Urology, Tel-Aviv Sourasky Medical Center, Sackler School of Medicine, Tel-Aviv University, Tel Aviv, Israel.
Introduction: We sought to develop a model that predicts lymph node invasion (LNI) in patients with intermediate- and high-risk prostate cancer incorporating preoperative clinical and Ga-prostate-specific membrane antigen positron emission tomography/computed tomography (PSMA PET/CT) parameters.
Methods: A cohort of 413 consecutive patients diagnosed with prostate cancer who underwent Ga- PSMA PET/CT prior to radical prostatectomy from 2015-2020 was used to develop and validate the model. The cohort was split into a learning (70%) and a validation group (30%).
[Clinical Value of Dual Tracer PET Imaging With Ga-PSMA and F-FDG in Patients With Metastatic Prostate Cancer].
Sichuan Da Xue Xue Bao Yi Xue Ban
September 2024
（ 610041） Department of Nuclear Medicine, West China Hospital, Sichuan University, Chengdu 610041, China.
Objective: In this study, we retrospectively analyzed the imaging characteristics of dual-tracer Ga-prostate specific membrane antigen (PSMA) and F-flurodeoxyglucose (FDG) positron emission tomography (PET)/computed tomography (CT) in metastatic prostate cancer (mPCa) patients. We analyzed the uptake modes of the dual tracers, explored clinical pathological parameters affecting the F-FDG uptake in the lesions, and evaluated their prognostic implications for prostate specific antigen progression-free survival (PSA-PFS).
Methods: A total of 41 mPCa patients who underwent dual-tracer PET/CT (Ga-PSMA and F-FDG) scans between September 2021 and January 2024 were retrospectively enrolled.
Paget's Disease Mimicking Prostate Cancer Metastasis with Ga-PSMA PET/CT.
Mol Imaging Radionucl Ther
October 2024
İstanbul University, İstanbul Faculty of Medicine, Department of Nuclear Medicine, İstanbul, Türkiye.
Article Synopsis
- Ga-PSMA imaging can find bone problems in men with prostate cancer!
- Not all spots found in bone are cancer; doctors need to check carefully!
- A 62-year-old man with early-stage prostate cancer had a spot that turned out to be something else called Paget's disease!
Assessing ChatGPT's summarization of Ga PSMA PET/CT reports for patients.
Abdom Radiol (NY)
September 2024
Recep Tayyip Erdogan University, Faculty of Medicine, Department of Radiology, Rize, Turkey.
Purpose: ChatGPT has recently been the subject of many studies, and its responses to medical questions have been successful. We examined ChatGPT-4's evaluation of structured Ga prostate-specific membrane antigen (PSMA) PET/CT reports of newly diagnosed prostate cancer patients.
Methods: Ga PSMA PET/CT reports of 164 patients were entered to ChatGPT-4.
Intrapatient Intermetastatic Heterogeneity Determined by Triple-Tracer PET Imaging in mCRPC Patients and Correlation to Survival: The 3TMPO Cohort Study.
J Nucl Med
November 2024
Oncology Axis, CHU de Québec-Université Laval Research Center, Quebec City, Quebec, Canada.
Intrapatient intermetastatic heterogeneity (IIH) has been demonstrated in metastatic castration-resistant prostate cancer (mCRPC) patients and is of the utmost importance for radiopharmaceutical therapy (RPT) eligibility. This study was designed to determine the prevalence of IIH and RPT eligibility in mCRPC patients through a triple-tracer PET imaging strategy. This was a multisite prospective observational study in which mCRPC patients underwent both F-FDG and Ga-prostate-specific membrane antigen (PSMA)-617 PET/CT scans.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!